Abstracts

Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing

Very early antiretroviral treatment (ART) initiation in HIV infected newborns may limit the seeding of viral reservoirs and maintain immune responses, but few antiretroviral agents are approved for use in newborns. Prophylactic NVP dosing is well established, but the appropriate NVP dose for treatment, which requires higher NVP levels than prophylaxis, is still unknown.  While…

Pharmacokinetics, Safety, and Efficacy of Maraviroc in Pediatric Patients With R5 HIV

Maraviroc (MVC) is a CCR5 antagonist approved to treat adults infected with CCR5-tropic (R5) HIV-1. Study A4001031 was conducted to evaluate the pharmacokinetics (PK), safety and efficacy of MVC in treatment-experienced (TE) pediatric patients. This is an open-label, two-stage (stage 1: dose-finding; stage 2: safety/efficacy), age-stratified, non-comparative, multicenter study to evaluate the PK, safety and…

Safety of Tenofovir on Bone Mineral Density in HIV-Infected Youths: A 10-Year Study

HIV-infected adults receiving highly active antiretroviral therapy (HAART) containing  tenofovir DF (TDF) have decreased bone mineral density (BMD) measurements. Data in children are conflicting. The aim of this study was to assess the long-term safety of a TDF-containing HAART on BMD in a cohort of  pediatric patients. This was a single-site, longitudinal, controlled, observational study.…

Nevirapine (NVP) Concentrations in HIV-Infected Newborns Receiving Therapeutic Dosing

Very early antiretroviral treatment (ART) initiation in HIV infected newborns may limit the seeding of viral reservoirs and maintain immune responses, but few antiretroviral agents are approved for use in newborns. Prophylactic NVP dosing is well established, but the appropriate NVP dose for treatment, which requires higher NVP levels than prophylaxis, is still unknown.  While…

Safety of Tenofovir on Bone Mineral Density in HIV-Infected Youths: A 10-Year Study

HIV-infected adults receiving highly active antiretroviral therapy (HAART) containing  tenofovir DF (TDF) have decreased bone mineral density (BMD) measurements. Data in children are conflicting. The aim of this study was to assess the long-term safety of a TDF-containing HAART on BMD in a cohort of  pediatric patients. This was a single-site, longitudinal, controlled, observational study.…